Anteris Technologies Global Corp.
AVR
NASDAQ·Healthcare·Medical - Devices·Mkt cap $879.0M
$9.04
▲ +3.67%
P/E
-2.63
Mkt Cap
$879.0M
52-Wk Range
$3.30–$11.06
52-Week Range
$3.30 - $11.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 94.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ADAPT anti-calcification technology extending valve durability and reducing reoperation rates
- DurAVR valve design mimics natural aortic valve biomechanics for superior hemodynamic performance
- ComASUR physician-developed delivery system enabling precise catheter control and reduced procedural complications
- Experienced management team with deep structural heart expertise and regulatory pathway knowledge
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Strong growth ahead
Expanding global aortic stenosis patient population and aging demographics driving demand for valve replacements
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Stable
-3.2% over 3m
Quality
Stable
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying AVR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.30 vs -$0.21 consensus (-44.7% surprise). Revenue of $1.1M vs $1.5M expected (-26.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-44.7%
Revenue trend · last 8Q
—
-1%
-27%
-2%
-44%
-42%
-11%
+63%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$548.5K
$382.4K
$396.6K
$440.9K
$306.0K
$221.1K
$352.4K
$1.0M
Margins · last 8Q
Gross
76.9%
Profit
-2852.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · $18.00 · May 15, 2026
vs Industry
How AVR stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related